S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults.

Lana TranMina NikanjamEdmund V CapparelliJoseph S BertinoAnne N NafzigerAngela D M KashubaSandrine TurpaultJoseph D Ma

Published in: European journal of clinical pharmacology (2021)

Phenotyping studies with S-warfarin in healthy subjects can utilize a single- and/or a 2-timepoint LSM with a population PK approach to estimate constitutive CYP2C9 activity.

Keyphrases

atrial fibrillation
venous thromboembolism
direct oral anticoagulants
high throughput